Roche Presented Vabysmo Real-World Data
The pharmaceutical company shared findings from a 5,000-patient study regarding the efficacy of its vision treatment.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you trust that new medical treatments work as well in real-world practice as in trials?
Roche has unveiled new real-world data from the VOYAGER study, which evaluated the effectiveness and safety of Vabysmo. The study analyzed data from patients across 28 countries to assess the bispecific antibody's impact on multiple vision-threatening conditions.
Why it matters
This extensive study provides evidence for how the drug performs in diverse, real-world clinical settings beyond controlled trials. These results help clinicians and health authorities verify the long-term safety and effectiveness of the treatment in practice.
The VOYAGER study utilized AI and deep learning algorithms to analyze SD-OCT imaging data from 5,000 patients. Vabysmo targets the Ang-2 and VEGF-A pathways, which are critical in treating nAMD, DME, and RVO.
The players
Roche
This Swiss multinational healthcare company is one of the world's largest pharmaceutical firms and a leader in biotechnology and diagnostics.
The details
Researchers observed vision and central subfield thickness improvements in patients with nAMD and DME, alongside clinical efficacy in those with RVO. The analysis of this large, multi-country cohort confirmed the drug's safety profile with no new safety signals detected.
Timeline
The data was presented at the EURETINA 2026 congress, which took place from October 1-4, 2026.
The Tech Race
The VOYAGER study follows the protocol of established large-scale medical research programs to validate therapeutic performance in global clinical practice. This shift toward using AI-driven analysis of real-world imaging data is increasingly replacing smaller, traditional observational studies in the biotech industry.
Patients and healthcare providers can use these findings to better understand the expected clinical outcomes and safety profile of Vabysmo in actual practice. The data supports broader global confidence as Vabysmo maintains regulatory approval in more than 100 countries.
The takeaway
Large-scale real-world data analysis is becoming a critical tool for medical professionals to confirm the efficacy of pharmaceutical interventions outside of controlled trial environments. These findings reinforce the clinical standard for treating complex vision-threatening eye conditions globally.
Further reading
Find more insights into the evolving landscape of medical research in our Biotech section.
Live Poll
Do you trust that new medical treatments work as well in real-world practice as in trials?
